Q2 sales went up strongly by +39% (organic: -1%) to €2,106m and the gross profit margin improved from 18.1% to 20.3%. EBITDA ramped up by +35% to €254m and net income attributable to shareholders more than doubled (€133m after €50m). In H1, the operating CF benefited from the far higher operating performance coming in at €254m (€174m). Due to the Bostik acquisition, investing CF swelled from €-271m to €-1,531m, of which €-1,298m is attributable to
31 Jul 2015
Weak organic performance, but FX and Bostik drove the pace
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Weak organic performance, but FX and Bostik drove the pace
Arkema SA (AKE:WBO) | 0 0 0.4% | Mkt Cap: 7,655m
- Published:
31 Jul 2015 -
Author:
Martin Schnee -
Pages:
2
Q2 sales went up strongly by +39% (organic: -1%) to €2,106m and the gross profit margin improved from 18.1% to 20.3%. EBITDA ramped up by +35% to €254m and net income attributable to shareholders more than doubled (€133m after €50m). In H1, the operating CF benefited from the far higher operating performance coming in at €254m (€174m). Due to the Bostik acquisition, investing CF swelled from €-271m to €-1,531m, of which €-1,298m is attributable to